Business
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations NORTH BILLERICA, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations\nNORTH BILLERICA, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced two key management promotions. Paul Blanchfield has been promoted to Chief Operating Officer (COO) and will continue to report to Mary Anne Heino, President and CEO. In addition, Dottie Barr has been promoted to Senior Vice President, Manufacturing and Technical Operations (SVP, Mfg & Tech Ops) and will report to Paul Blanchfield. Both promotions are effective immediately. “We are confident that elevating Paul and Dottie to these roles will maximize their talents and enable us to continue to execute on our strategic purpose to Find, Fight, and Follow disease to deliver better patient outcomes,” commented Mary Anne Heino, Lantheus President and CEO. “With their expertise in commercial excellence and complex manufacturing and supply chains, both Paul and Dottie have been instrumental in the stellar performance of our business to date. They have consistently demonstrated exemplary leadership and results-driven and long-term strategic thinking, while always putting patients first.” Mr. Blanchfield joined Lantheus as Chief Commercial Officer in January 2020. Together with his team, he successfully launched the Company’s PSMA PET imaging agent for prostate cancer; continued to grow the Company’s microbubble franchise; and led the commercial team through the changing COVID-19 environment. In his new role, Mr. Blanchfield will have responsibility for Commercial, Manufacturing and Technical Operations, Quality, and Corporate Communications. Prior to Lantheus, he worked at Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion-dollar P&L covering multiple rare disease products. Prior to Takeda, Mr. Blanchfield worked at Shire Plc for almost six years across several different roles, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy, and Chief of Staff to the CEO. Mr. Blanchfield started his career at McKinsey & Company, where he focused on health care, marketing, and sales. He earned an MBA/MA in Education from Stanford University and an AB in Economics from Duke University. Ms. Barr joined Lantheus more than f...